<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MITOSOL- mitomycin 
			 </strong><br>Mobius Therapeutics LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Mitosol<span class="Sup">®</span> (mitomycin for solution) safely and effectively. See full prescribing information for Mitosol<span class="Sup">®</span> (mitomycin for solution).<br>Mitosol<span class="Sup">®</span> (mitomycin for solution)<br>Initial U.S. Approval: 1974
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Mitosol<span class="Sup">®</span> is an antimetabolite indicated as an adjunct to ab externo <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> surgery. (<a href="#s1">1</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Mitosol<span class="Sup">®</span> is intended for topical application to the surgical site of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> filtration surgery. It is not intended for intraocular administration. (<a href="#s2">2</a>)
 </p>
<ul class="Disc">
<li>Each vial of Mitosol<span class="Sup">®</span> contains 0.2 mg of mitomycin and mannitol in a 1:2 concentration ratio. To reconstitute, add 1 mL of Sterile Water for Injection, then shake to dissolve. If product does not dissolve immediately, allow to stand at room temperature until the product has dissolved into solution. (<a href="#s3">2.1</a>)
</li>
<li>Fully saturate sponges provided within the Mitosol<span class="Sup">®</span> Kit utilizing the entire reconstituted contents of the vial in the manner prescribed in the Instructions for Use. (<a href="#s4">2.2</a>)
</li>
<li>Apply fully saturated sponges equally to the treatment area, in a single layer, with the use of a surgical forceps. Keep the sponges on the treatment area for two (2) minutes, then remove and return to the Mitosol<span class="Sup">®</span> Tray for defined disposal. (<a href="#s4">2.2</a>)
</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Each vial contains a sterile lyophilized mixture of 0.2 mg mitomycin and 0.4 mg mannitol; when reconstituted with Sterile Water for Injection, the solution contains 0.2 mg/mL mitomycin. (<a href="#s6">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to mitomycin. (<a href="#s8">4.1</a>)
</li>
<li>Women who are or may become pregnant during therapy. (<a href="#s9">4.2</a>)
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4034461" conceptname="Cytolysis">Cell Death</span>. Mitomycin is cytotoxic. Use of mitomycin in concentrations higher than 0.2 mg/mL or use for longer than 2 minutes may lead to unintended corneal and/or scleral damage including thinning or perforation. Direct contact with the corneal endothelium will result in <span class="product-label-link" type="condition" conceptid="4034461" conceptname="Cytolysis">cell death</span>. (<a href="#s11">5.1</a>)
</li>
<li>Hypotony. The use of mitomycin has been associated with an increased instance of post-operative hypotony. (<a href="#s12">5.2</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataract</span> Development. Use in phakic patients has been correlated to a higher instance of lenticular change and <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> formation. (<a href="#s13">5.3</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most frequent adverse reactions to Mitosol<span class="Sup">®</span> occur locally and include hypotony, hypotony <span class="product-label-link" type="condition" conceptid="4208223" conceptname="Disorder of macula of retina">maculopathy</span>, blebitis, <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">endophthalmitis</span>, vascular reactions, corneal reactions, and <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>. (<a href="#s15">6.1</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Mobius Therapeutics LLC at 1-877-393-6486 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 1/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1. INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">2. DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Method of Reconstitution:
</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Method of Use:
</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Stability
</a></h2>
<h1><a href="#section-3" class="toc">3. DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4. CONTRAINDICATIONS
</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Pregnant women
</a></h2>
<h1><a href="#section-5" class="toc">5. WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4034461" conceptname="Cytolysis">Cell Death</span>
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Hypotony
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3   <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataract</span> Formation
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Ophthalmic Adverse Reactions
</a></h2>
<h1><a href="#section-7" class="toc">8.  USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">8.1  Pregnancy
</a></h2>
<h2><a href="#section-7.2" class="toc">8.3  Nursing Mothers
</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use
</a></h2>
<h1><a href="#section-8" class="toc">11.  DESCRIPTION
</a></h1>
<h1><a href="#section-9" class="toc">12. CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-9.2" class="toc">12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-10" class="toc">13. NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-11" class="toc">14. CLINICAL STUDIES
</a></h1>
<h1><a href="#section-12" class="toc">16. HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h2><a href="#section-12.1" class="toc">16.1 How Supplied
</a></h2>
<h2><a href="#section-12.2" class="toc">16.2 Storage and Handling
</a></h2>
<h1><a href="#section-13" class="toc">17. PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1. INDICATIONS AND USAGE
</h1>
<p class="First">Mitosol<span class="Sup">®</span> is an antimetabolite indicated for use as an adjunct to ab externo <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> surgery.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2. DOSAGE AND ADMINISTRATION
</h1>
<p class="First">Mitosol<span class="Sup">®</span> is intended for topical application to the surgical site of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> filtration surgery. It is not intended for intraocular administration. If intraocular administration occurs, <span class="product-label-link" type="condition" conceptid="4034461" conceptname="Cytolysis">cell death</span> leading to corneal <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, retinal <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, and ciliary body <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> may result.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Method of Reconstitution:
</h2>
<p class="First">Each vial of Mitosol<span class="Sup">®</span> contains 0.2 mg of mitomycin and mannitol in a 1:2 concentration ratio. To reconstitute, add 1 ml_ of Sterile Water for Injection, then shake to dissolve. If product does not dissolve immediately, allow to stand at room temperature until the product dissolves into solution.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Method of Use:
</h2>
<p class="First">Sponges provided within the Mitosol<span class="Sup">®</span> Kit should be fully saturated with the entire reconstituted contents in the manner prescribed in the Instructions for Use. A treatment area approximating 10mm x 6mm +/-2mm should be treated with the Mitosol<span class="Sup">®</span>. Apply fully saturated sponges equally to the treatment area, in a single layer, with the use of a surgical forceps. Keep the sponges on the treatment area for two (2) minutes, then remove and return to the Mitosol<span class="Sup">®</span> Tray for defined disposal in the Chemotherapy Waste Bag provided.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Stability
</h2>
<p class="First"><span class="Italics">Lyophilized</span> Mitosol<span class="Sup">®</span> stored at controlled room temperature (i.e., 20 - 25°C or 68° - 77° F) is stable for the shelf life indicated on the package. Avoid excessive heat. Protect from light.
</p>
<p><span class="Italics">Reconstituted</span> with Sterile Water for Injection at a concentration of 0.2 mg/ml, mitomycin is stable for one (1) hour at room temperature.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s6"></a><a name="section-3"></a><p></p>
<h1>3. DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Mitosol<span class="Sup">®</span> is a sterile lyophilized mixture of mitomycin and mannitol, which, when reconstituted with Sterile Water for Injection, provides a solution for application in <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> filtration surgery. Mitosol<span class="Sup">®</span> is supplied in vials containing 0.2 mg of mitomycin. Each vial also contains mannitol 0.4 mg, at a 1:2 ratio of mitomycin to mannitol. Each mL of reconstituted solution contains 0.2 mg mitomycin and has a pH between 5.0 and 8.0.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s7"></a><a name="section-4"></a><p></p>
<h1>4. CONTRAINDICATIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-4.1"></a><p></p>
<h2>4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</h2>
<p class="First">Mitosol<span class="Sup">®</span> is contraindicated in patients that have demonstrated a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to mitomycin in the past.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Pregnant women
</h2>
<p class="First">Mitosol<span class="Sup">®</span> may cause fetal harm when administered to a pregnant woman. Mitomycin administered parenterally has been shown to be teratogenic in mice and rats when given at doses equivalent to the usual human intravenous dose. Mitosol<span class="Sup">®</span> is contraindicated in women who are or may become pregnant during therapy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s10"></a><a name="section-5"></a><p></p>
<h1>5. WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4034461" conceptname="Cytolysis">Cell Death</span>
</h2>
<p class="First">Mitomycin is cytotoxic. Use of mitomycin in concentrations higher than 0.2 mg/mL or use for longer than 2 minutes may lead to unintended corneal and/or scleral damage including thinning or perforation. Direct contact with the corneal endothelium will result in <span class="product-label-link" type="condition" conceptid="4034461" conceptname="Cytolysis">cell death</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Hypotony
</h2>
<p class="First">The use of mitomycin has been associated with an increased instance of post-operative hypotony.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-5.3"></a><p></p>
<h2>5.3   <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataract</span> Formation
</h2>
<p class="First">Use in phakic patients has been correlated to a higher instance of lenticular change and <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> formation.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s14"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Ophthalmic Adverse Reactions
</h2>
<p class="First">The most frequent adverse reactions to Mitosol<span class="Sup">®</span> occur locally, as an extension of the pharmacological activity of the drug. These reactions include:
</p>
<p><span class="Italics">Blebitis:</span> bleb ulceration, chronic bleb leak, encapsulated/cystic bleb, bleb-related <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="439981" conceptname="Wound dehiscence">wound dehiscence</span>, conjunctivial <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, thin-walled bleb
</p>
<p><span class="Italics">Cornea:</span> corneal endothelial damage, epithelial defect, anterior synechiae, superficial punctuate <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, Descemet's detachment, induced <span class="product-label-link" type="condition" conceptid="378424" conceptname="Astigmatism">astigmatism</span>
</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">Endophthalmitis</span></span></p>
<p><span class="Italics">Hypotony:</span> choroidal reactions (<span class="product-label-link" type="condition" conceptid="437860" conceptname="Choroidal detachment">choroidal detachment</span>, choroidal <span class="product-label-link" type="condition" conceptid="4215818" conceptname="Effusion">effusion</span>, <span class="product-label-link" type="condition" conceptid="437860" conceptname="Choroidal detachment">serous choroidal detachment</span>, suprachoroidal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, hypotony <span class="product-label-link" type="condition" conceptid="4208223" conceptname="Disorder of macula of retina">maculopathy</span>, presence of supraciliochoroidal fluid, hypoechogenic suprachoroidal <span class="product-label-link" type="condition" conceptid="4215818" conceptname="Effusion">effusion</span>)
</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span>:</span> <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, fibrin reaction
</p>
<p><span class="Italics">Lens:</span> <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> development, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> progression, capsule opacification, capsular constriction and/or capsulotomy rupture, posterior synechiae
</p>
<p><span class="Italics">Retina:</span> retinal pigment epithelial tear, <span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">retinal detachment</span> (serous and rhegatogenous)
</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="434944" conceptname="Scleritis">Scleritis</span>:</span> <span class="product-label-link" type="condition" conceptid="439981" conceptname="Wound dehiscence">wound dehiscence</span>
</p>
<p><span class="Italics">Vascular:</span> <span class="product-label-link" type="condition" conceptid="432904" conceptname="Hyphema">hyphema</span>, <span class="product-label-link" type="condition" conceptid="313761" conceptname="Central retinal vein occlusion">central retinal vein occlusion</span>, <span class="product-label-link" type="condition" conceptid="313761" conceptname="Central retinal vein occlusion">hemiretinal vein occlusion</span>, <span class="product-label-link" type="condition" conceptid="374025" conceptname="Retinal hemorrhage">retinal hemorrhage</span>, vitreal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and blood clot, <span class="product-label-link" type="condition" conceptid="378756" conceptname="Conjunctival hemorrhage">subconjunctival hemorrhage</span>, disk <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>
</p>
<p><span class="Italics">Additional Reactions:</span> <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>, sclera thinning or ulceration, intraocular lens capture, disk <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, malignant <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, lacrimal drainage system obstruction, ciliary block, corneal vascularization, visual acuity decrease, cystic conjunctival degeneration, upper <span class="product-label-link" type="condition" conceptid="443794" conceptname="Lid retraction">eyelid retraction</span>, dislocated implants, severe <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s16"></a><a name="section-7"></a><p></p>
<h1>8.  USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s17"></a><a name="section-7.1"></a><p></p>
<h2>8.1  Pregnancy
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="e17"></a><a name="section-7.1.1"></a><p></p>
<p class="First">Teratogenic Effects: Pregnancy Category X <span class="Italics">(see Contraindications, <a href="#s9">4.2</a>).</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s18"></a><a name="section-7.2"></a><p></p>
<h2>8.3  Nursing Mothers
</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from Mitosol<span class="Sup">®</span>, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. It is recommended that women receiving Mitosol<span class="Sup">®</span> not breast feed because of the potential for serious adverse reactions in nursing infants.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s19"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s20"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">No overall differences in safety and effectiveness have been observed between elderly and younger patients.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s21"></a><a name="section-8"></a><p></p>
<h1>11.  DESCRIPTION
</h1>
<p class="First">Mitomycin is an antibiotic isolated from the broth of <span class="Italics">Streptomyces verticillus Yingtanensis</span> which has been shown to have antimetabolic activity.
</p>
<p>Mitomycin is a blue-violet crystalline powder with the molecular formula of C<span class="Sub">15</span>H<span class="Sub">18</span>N<span class="Sub">4</span>0<span class="Sub">5</span> and a molecular weight of 334.33. Its chemical name is 7-amino-9α-methoxymitosane and it has the following structural formula:
</p>
<p><a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=244002c6-c61d-43fe-9326-072797113979&amp;name=mit00-0003-01.jpg"></p>
<p>Mitosol<span class="Sup">®</span> is a sterile lyophiliized mixture of mitomycin and mannitol, which, when reconstituted with Sterile Water for Injection, provides a solution for application in <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> filtration surgery. Mitosol<span class="Sup">®</span> is supplied in vials containing 0.2 mg of mitomycin. Each vial also contains mannitol 0.4 mg, at a 1:2 ratio of mitomycin to mannitol. Each mL of reconstituted solution contains 0.2 mg mitomycin and has a pH between 5.0 and 8.0.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s22"></a><a name="section-9"></a><p></p>
<h1>12. CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s23"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">Mitosol<span class="Sup">®</span> inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. Cellular RNA and protein synthesis may also be suppressed.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s24"></a><a name="section-9.2"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-9.2.1"></a><p></p>
<p class="First"><span class="Italics">Absorption</span></p>
<p>The systemic exposure of mitomycin following ocular administration of Mitosol<span class="Sup">®</span> in humans is unknown. Based on a comparison of the proposed dose of up to 0.2 mg to intravenous (IV) doses of mitomycin used clinically for treatment of oncologic indications (up to 20 mg/m<span class="Sup">2</span>), systemic concentrations in humans upon ocular administration are expected to be multiple orders of magnitude lower than those achieved by IV administration.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-9.2.2"></a><p></p>
<p class="First"><span class="Italics">Metabolism</span></p>
<p>In humans, mitomycin is cleared from ophthalmic tissue after intraoperative topical application and irrigation, as metabolism occurs in other affected tissues. Systemic clearance is affected primarily by metabolism in the liver. The rate of clearance is inversely proportional to the maximal serum concentration because of saturation of the degradative pathways.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-9.2.3"></a><p></p>
<p class="First"><span class="Italics">Excretion</span></p>
<p>Approximately 10% of an injectable dose of mitomycin is excreted unchanged in the urine. Since metabolic pathways are saturated at relatively low doses, the percent of a dose excreted in urine increases.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s28"></a><a name="section-10"></a><p></p>
<h1>13. NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s29"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Adequate long-term studies in animals to evaluate carcinogenic potential have not been conducted with Mitosol<span class="Sup">®</span>. Intravenous administration of mitomycin has been found to be carcinogenic in rats and mice. At doses approximating the recommended clinical injectable dose in humans, mitomycin produces a greater than 100 percent increase in tumor incidence in male Sprague-Dawley rats, and a greater than 50 percent increase in tumor incidence in female Swiss mice. The effect of Mitosol<span class="Sup">®</span> on fertility is unknown.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s30"></a><a name="section-11"></a><p></p>
<h1>14. CLINICAL STUDIES
</h1>
<p class="First">In placebo-controlled studies reported in the medical literature, mitomycin reduced intraocular pressure (IOP) by 3 mmHg in patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> when used as an adjunct to ab externo <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> surgery by Month 12. In studies with a historical control reported in the medical literature, mitomycin reduced intraocular pressure (IOP) by 5 mmHg in patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> when used as an adjunct to ab externo <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> surgery by Month 12.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s31"></a><a name="section-12"></a><p></p>
<h1>16. HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-12.1"></a><p></p>
<h2>16.1 How Supplied
</h2>
<p class="First">Mitosol<span class="Sup">®</span> (mitomycin for solution) is available in a kit containing:
</p>
<p>One             Vial containing 0.2 mg mitomycin
</p>
<p>One             1 mL syringe (Sterile Water For Injection) with Connector
</p>
<p>One             Plunger Rod
</p>
<p>One             Vial Adapter with Spike
</p>
<p>One             1 mLTB Syringe, Luer Lock
</p>
<p>One             Sponge Container
</p>
<p>Six               3 mm Absorbent Sponges
</p>
<p>Six               6 mm Absorbent Sponges
</p>
<p>Six               Half Moon Sponges
</p>
<p>One             Instrument Wedge Sponge
</p>
<p>One             Alcohol Prep Pad, Sterile
</p>
<p>One             Chemotherapy Waste Bag
</p>
<p>Three kits are supplied in each carton (NDC49771-002-03).
</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="s33"></a><a name="section-12.2"></a><p></p>
<h2>16.2 Storage and Handling
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-12.2.1"></a><p></p>
<p class="First"><span class="Italics">Storage</span></p>
<p>Store kits at 20° - 25° C (68° - 77° F). Protect from light.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-12.2.2"></a><p></p>
<p class="First"><span class="Italics">Handling Procedures</span></p>
<p>Procedures for Proper Handling and Disposal of anti-cancer drugs should be followed. Appropriate containment and disposal devices are included within the Mitosol<span class="Sup">®</span> (mitomycin for solution) Kit for Ophthalmic Use.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s36"></a><a name="section-13"></a><p></p>
<h1>17. PATIENT COUNSELING INFORMATION
</h1>
<ul class="Disc">
<li>Instruct patients to discuss with their physician if they are pregnant or if they might become pregnant <span class="Italics">(see Contraindications, <a href="#s9">4.2</a>).</span>
</li>
<li>Instruct patients to discuss with their physician if they have demonstrated a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to mitomycin in the past <span class="Italics">(see Contraindications, <a href="#s8">4.1</a>).</span>
</li>
<li>Nursing mothers should be advised that it is not known if Mitosol<span class="Sup">®</span> is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue use of the drug, taking into account the importance of the drug to the mother. It is recommended that women receiving Mitosol<span class="Sup">®</span> not breast feed because of the potential for serious adverse reactions in nursing infants <span class="Italics">(see Use in Specific Populations, <a href="#s18">8.3</a>).</span>
</li>
<li>Patients should be advised of the toxicity of Mitosol<span class="Sup">®</span> and potential complications.
</li>
</ul>
<p class="First">Manufactured for:<br>Mobius Therapeutics, LLC<br>4041 Forest Park Avenue<br>St. Louis, MO 63108
</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="s37"></a><a name="section-14"></a><p></p>
<p class="First"><span class="Bold">Mitosol</span><span class="Sup">®
</span><br>(mitomycin for solution)<br>0.2 mg/vial<br><span class="Bold">Kit for Ophthalmic Use</span></p>
<p><span class="Bold Underline">Read INSTRUCTIONS FOR USE Before Proceeding</span></p>
<p><span class="Bold">Instructions for Use</span></p>
<table width="100%">
<col align="left" width="50.000%">
<col align="left" width="50.000%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">A.    <span class="Bold">Black Outer Pack</span> (<a href="#f02">Figure A</a>)<br><dl>
<dt> 
</dt>
<dd>One   Chemotherapy Waste Bag
</dd>
<dt> 
</dt>
<dd>One   Instructions for Use
</dd>
<dt> 
</dt>
<dd>One   Package Insert
</dd>
<dt> 
</dt>
<dd>One   Inner Tray
</dd>
</dl>
<span class="Italics">The Black Outer Pack is to be handled, opened, and its
</span><span class="Bold">STERILE
</span><span class="Italics">contents dispensed by the non-sterile circulating nurse.</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<a name="f02"></a><img alt="Figure A
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=244002c6-c61d-43fe-9326-072797113979&amp;name=mit00-0003-02.jpg"><span class="Bold">Figure A: Black Outer Pack</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">B.  <span class="Bold">STERILE Inner Tray</span> (<a href="#f03">Figure B</a>)<dl>
<dt> 
</dt>
<dd>One   Vial Containing 0.2 mg mitomycin
</dd>
<dt> 
</dt>
<dd>One   1 mL Syringe (Sterile Water for Injection) with Connector    
</dd>
<dt> 
</dt>
<dd>One    Plunger Rod
</dd>
<dt> 
</dt>
<dd>One   Vial Adaptor with Spike
</dd>
<dt> 
</dt>
<dd>One   1 mL TB Syringe, Luer Lock
</dd>
<dt> 
</dt>
<dd>One   Sponge Container
</dd>
<dt> 
</dt>
<dd>Six   3 mm Absorbent Sponges
</dd>
<dt> 
</dt>
<dd>Six   6 mm Absorbent Sponges
</dd>
<dt> 
</dt>
<dd>Six   Half Moon Sponges
</dd>
<dt> 
</dt>
<dd>One   Instrument Wedge Sponge
</dd>
<dt> 
</dt>
<dd>One   Alcohol Prep Pad, Sterile
</dd>
</dl>
<span class="Italics">The Sterile Inner Tray is to be handled, opened, and its contents assembled and dispensed by the sterile scrub technician.<br></span><span class="Bold Italics">This tray and its contents are STERILE.</span><br>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<a name="f03"></a><img alt="Figure B
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=244002c6-c61d-43fe-9326-072797113979&amp;name=mit00-0003-03.jpg"><span class="Bold">Figure B: Sterile Inner Tray</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">1. Getting Started</span><br><dl>
<dt> 
</dt>
<dd><span class="Bold Underline">Non-Sterile Circulating Nurse:</span></dd>
<dt> 
</dt>
<dd>Open black outer pack. Affect sterile transfer of contents to the sterile field.
</dd>
<dt> 
</dt>
<dd><span class="Bold Underline">Sterile Surgical Technician:</span></dd>
<dt> 
</dt>
<dd>Open sterile inner tray.
</dd>
</dl>
<span class="Bold">2. Reconstituting Mitosol</span><span class="Sup">®</span><br><dl>
<dt> 
</dt>
<dd>a. <span class="Bold Underline">Screw</span> white plunger rod to rubber plunger of pre-filled syringe. <span class="Bold">(<a href="#f04">Fig. 1</a>)</span>
</dd>
<dt> 
</dt>
<dd>b. <span class="Bold Underline">Press firmly</span> and screw the <span class="Bold Underline">blue end</span> of the vial adapter into the <span class="Bold Underline">blue end</span> of the syringe connector. <span class="Bold">(<a href="#f05">Fig. 2</a>)</span><br>
</dd>
</dl>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<a name="f04"></a><img alt="Figure 1
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=244002c6-c61d-43fe-9326-072797113979&amp;name=mit00-0003-04.jpg"><a name="f05"></a><img alt="Figure 2
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=244002c6-c61d-43fe-9326-072797113979&amp;name=mit00-0003-05.jpg">
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><dl>
<dt> 
</dt>
<dd>c. Open and remove alcohol prep pad. Remove vial cap; disinfect vial stopper with alcohol prep pad.
</dd>
<dt> 
</dt>
<dd>d. Holding vial face up, push spiked end of vial adapter down on the vial lid until seated and secure. <span class="Bold">(<a href="#f06">Fig. 3</a>)</span><br>
</dd>
</dl></td>
<td class="Botrule Rrule" align="center" valign="top">
<a name="f06"></a><img alt="Figure 3
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=244002c6-c61d-43fe-9326-072797113979&amp;name=mit00-0003-06.jpg">
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><dl>
<dt> 
</dt>
<dd>e. Inject entire contents of sterile water (1 ml) into vial. <span class="Bold">(<a href="#f07">Fig. 4</a>)</span>
</dd>
<dt> 
</dt>
<dd>f. Gently swirl vial and contents until complete reconstitution of Miosol<span class="Sup">®</span>. If product does not dissolve immediately, allow to stand at room temperature until the product has dissolved into solution.
</dd>
</dl></td>
<td class="Botrule Rrule" align="center" valign="top">
<a name="f07"></a><img alt="Figure 4
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=244002c6-c61d-43fe-9326-072797113979&amp;name=mit00-0003-07.jpg"><span class="Bold"></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">3. Preparing sponges</span><br><dl>
<dt> 
</dt>
<dd>a. <span class="Bold Italics">Invert vial and syringe</span> and draw full volume of medication into syringe.
</dd>
<dt> 
</dt>
<dd>b. Unscrew the syringe and connector from vial and vial adapter <span class="Bold">(<a href="#f09">Fig. 6</a>)</span><br>
</dd>
</dl>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<a name="f08"></a><img alt="Figure 5
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=244002c6-c61d-43fe-9326-072797113979&amp;name=mit00-0003-08.jpg"><span class="Bold"></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><dl>
<dt> 
</dt>
<dd>c. Place vial and vial adaptor in chemotherapy waste disposal bag (yellow bag).
</dd>
<dt> 
</dt>
<dd>d. Take sponge container from sterile inner tray
</dd>
<dt> 
</dt>
<dd>e. Screw both syringes into sponge container; the TB syringe to one end, the pre-filled syringe to the other.<br>
</dd>
</dl></td>
<td class="Botrule Rrule" align="center" valign="top">
<a name="f09"></a><img alt="Figure 6
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=244002c6-c61d-43fe-9326-072797113979&amp;name=mit00-0003-09.jpg"><span class="Bold"></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<dl>
<dt> 
</dt>
<dd>f. <span class="Bold Italics">Mitosol</span> <span class="Sup">®</span><span class="Bold Italics"> must be used within 1 hour of reconstitution:</span>
</dd>
</dl>
<ul class="Disc">
<li>Inject medication into sponge container, saturating sponges. Reconstituted Mitosol<span class="Sup">®</span> should remain undisturbed in sponge container for 60 seconds. <span class="Bold">(<a href="#f10">Fig. 7</a>)</span>
</li>
<li>If any excess fluid remains, withdraw plunger of TB syringe, drawing excess fluid/air into syringe.<br>
</li>
</ul>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<a name="f10"></a><img alt="Figure 7
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=244002c6-c61d-43fe-9326-072797113979&amp;name=mit00-0003-10.jpg"><span class="Bold"></span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">4.  Using Mitosol</span><span class="Sup">®</span><br><dl>
<dt> 
</dt>
<dd>a. With both syringes connected, the TB syringe to one end, the pre-filled syringe to the other, open sponge container, offering contents to surgeon for placement on surgical site. <span class="Bold">(<a href="#f11">Fig. 8</a>)</span>
</dd>
<dt> 
</dt>
<dd>b. Apply saturated sponges to surgical site for two minutes. Remove sponges from eye and copiously irrigate surgical site.
</dd>
<dt> 
</dt>
<dd>c. As used sponges are removed from surgical site, accept back into container for disposal. Close container lid.
</dd>
<dt> 
</dt>
<dd>d. With syringes still connected to sponge container, remove entire assembly from surgical field in chemotherapy waste disposal bag.<br>
</dd>
</dl>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<a name="f11"></a><img alt="Figure 8
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=244002c6-c61d-43fe-9326-072797113979&amp;name=mit00-0003-11.jpg"><span class="Bold"></span>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold Underline">DISPOSE OF CHEMOTHERAPY WASTE BAG AND ITS CONTENTS AS CHEMOTHERAPY WASTE</span></p>
<p><span class="Bold">MOB0022 Rev. D</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s38"></a><a name="section-15"></a><p></p>
<p class="First">Principal Display Panel – Carton Label
</p>
<p><span class="Bold">Mitosol</span><span class="Sup">®</span><br>(mitomycin for solution)
</p>
<p>0.2 mg/vial<br><span class="Bold">Kit for Ophthalmic Use</span></p>
<p>Manufactured for:<br>Mobius Therapeutics, LLC<br>4041 Forest Park Avenue<br>St. Louis, MO 63108 USA<br>+1 314-615-6930<br>1-877-EYE-MITO (1-877-393-6486)
</p>
<p><span class="Bold">Rx ONLY<br></span>US Pat #: 7,806,265;<br>other US and Int'l Patents Pending<br>©2010 Mobius Therapeutics, LLC
</p>
<p><span class="Bold">Mobius<br></span>therapeutics™<br>MOB0020 Rev. C<br></p>
<p>NDC #49771-002-03<br>Re-Order #MOB.2<br><span class="Bold">Contains 3 Kits</span></p>
<p>Each Mitosol<span class="Sup">®</span> Kit Contains:<br>One        Chemotherapy Waste Bag<br>One        Instructions for Use<br>One        Package Insert<br>One        Inner Tray
</p>
<p>Inner Tray Contains:
</p>
<p>One        Vial Containing 0.2 mg mitomycin<br>One        1 mL Syringe (Sterile Water for Injection) with Connector
</p>
<p>One        Plunger Rod<br>One        Vial Adaptor with Spike
</p>
<p>One        1 mL TB Syringe, Luer Lock<br>One        Sponge Container<br>Six         3 mm Absorbent Sponges<br>Six         6 mm Absorbent Sponges<br>Six         Half Moon Sponges<br>One        Instrument Wedge Sponge<br>One        Alcohol Prep Pad, Sterile
</p>
<p><span class="Bold">Contents STERILE in unopened undamaged package.</span></p>
<p>Storage: Store kits at 20° - 25° C (68° - 77° F). Protect from light.
</p>
<div class="Figure">
<a name="f12"></a><img alt="Principal Display Panel – Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=244002c6-c61d-43fe-9326-072797113979&amp;name=mit00-0003-12.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s39"></a><a name="section-16"></a><p></p>
<p class="First">Principal Display Panel – Vial Label
</p>
<p>NDC 49771-002-02<br><span class="Bold">Mitosol</span><span class="Sup">®</span><br>(mitomycin for solution)<br>0.2 mg/vial<br>Lyophilized Mitomycin for<br>reconstitution<br>Protect from light.<br>Single Use Vial<br>Dose: See Package Insert.<br><span class="Bold">Rx Only</span></p>
<div class="Figure">
<a name="f13"></a><img alt="Principal Display Panel – Vial Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=244002c6-c61d-43fe-9326-072797113979&amp;name=mit00-0003-13.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MITOSOL 		
					</strong><br><span class="contentTableReg">mitomycin kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49771-002</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49771-002-03</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49771-002-01</td>
<td class="formItem">1  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, SINGLE-USE </td>
<td class="formItem">1 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 SYRINGE </td>
<td class="formItem">1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 3</strong></td>
<td class="formItem">1 APPLICATOR </td>
<td class="formItem">5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 3</td></tr>
<tr><td class="contentTableTitle">
<strong>MITOSOL 		
					</strong><br><span class="contentTableReg">mitomycin injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Mitomycin</strong> (Mitomycin) </td>
<td class="formItem">Mitomycin</td>
<td class="formItem">0.2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022572</td>
<td class="formItem">02/08/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 3</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">water injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 SYRINGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022572</td>
<td class="formItem">02/08/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 3 of 3</td></tr>
<tr><td class="contentTableTitle">
<strong>MEDLINE ALCOHOL PREP 		
					STERILE, MEDIUM</strong><br><span class="contentTableReg">isopropyl alcohol swab</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53329-805</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ISOPROPYL ALCOHOL</strong> (ISOPROPYL ALCOHOL) </td>
<td class="formItem">ISOPROPYL ALCOHOL</td>
<td class="formItem">70 mL  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53329-805-09</td>
<td class="formItem">1  in 1 PACKET</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">OTC monograph not final</td>
<td class="formItem">part333A</td>
<td class="formItem">01/01/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022572</td>
<td class="formItem">02/08/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mobius Therapeutics LLC
							(805642118)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Mobius Therapeutics LLC</td>
<td class="formItem"></td>
<td class="formItem">805642118</td>
<td class="formItem">MANUFACTURE(49771-002)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>078c847d-5716-4b3c-9b31-a75cfb2669d0</div>
<div>Set id: 244002c6-c61d-43fe-9326-072797113979</div>
<div>Version: 3</div>
<div>Effective Time: 20120229</div>
</div>
</div> <div class="DistributorName">Mobius Therapeutics LLC</div></p>
</body></html>
